Thrombin receptor antagonists

Details Thrombin receptor antagonists Thrombin receptor antagonists

2007-12-04

2007-12-04

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S284100, C514S337000

Reexamination Certificate

active

10412982

ABSTRACT:
Heterocyclic-substituted tricyclics of the formulaor a pharmaceutically acceptable salt thereof, wherein:the dotted line represents an optional single bond;represents an optional double bond;n is 0–2;Q is cycloalkyl, optionally substituted by R13and R14;R13and R14are independently selected from (C1–C6)alkyl, (C3–C8)cycloalkyl, —OH, (C1–C6)alkoxy, R27-aryl(C1–C6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; orR13and R14together form a spirocyclic or a heterospirocyclic ring of 3–6 atoms;Het is a mono- or bi-cyclic optionally substituted heteroaryl group; andB is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

REFERENCES:
patent: 4847265 (1989-07-01), Badorc et al.
patent: 5576328 (1996-11-01), Herbert et al.
patent: 6063847 (2000-05-01), Chackalamannil et al.
patent: 6326380 (2001-12-01), Chackalamannil
patent: 6429210 (2002-08-01), Bousquet et al.
patent: 6504030 (2003-01-01), Bousquet et al.
patent: 6645987 (2003-11-01), Chackalamannil et al.
patent: 6894065 (2005-05-01), Chackalamannil et al.
patent: 7037920 (2006-05-01), Chackalamannil et al.
patent: 2003/0203927 (2003-10-01), Chackalamannil
patent: 2004/0152736 (2004-08-01), Chackalamannil et al.
patent: 2004/0192753 (2004-09-01), Chackalamannil et al.
patent: 2006/0106050 (2006-05-01), Chakalamannil et al.
patent: WO 99/26943 (1999-06-01), None
patent: WO99/26943 (1999-06-01), None
patent: WO 01/96330 (2001-12-01), None
International Search Report; mailed Jul. 22, 2003, PCT #US 03/11510.
U.S. Appl. No. 10/755,066, filed Jul. 9, 2005.
Hsieh, et. al.; “Simultaneous determination of a drug candidate and its metabolite in rate plasma samples using ultrafast monolithic column high-performance liquid chromatography/tandem mass spectrometry”; Rapid Communications in Mass Spectrometry; 2002;16:944-950.
Bernatowicz; “Development of Potent Thrombin Receptor Antagonist Peptides”; J. Med. Chem.; 1996; 39:4879-4887.
Ahn, Ho-Sam et al. Binding of a thrombin receptor tethered ligand analogue to human platelet thrombin receptor. Mol Pharmacol. Feb. 1997;51(2):350-6.
Zhang, Han-Cheng et al. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J Med Chem. Mar. 29, 2001;44(7):1021-4.
Zhang, H.-C. et al; “Discovery and Optimization of a Novel Series of Thrombin Receptor (PAR-1) Antagonists: Potent, Selective Peptide Mimetics Based on Indole and Indazole Templates” J. Med. Chem.; (Letter); 2001; 44(7); 1021-1024.
Shaun R. Coughlin; “How the protease thrombin talks to cells.”; Proc. Natl. Acad. Sci. USA, vol. 98, pp. 11023-11027, Sep. 1999.
Grand Roger J.A. et al; “Cellular consequences of thrombin-receptor activation”, Biochem. J. 1996, vol. 313, pp. 353-368 (printed in Great Britain).
Ahn H S et al; “Nonpeptide thrombin receptor antagonists,”. Drugs of the Future 2001, 26 (11); 1065-1085.
Samuel Chackalamannil; “Thrombin receptor antagonists as novel therapeutic targets”, Drug Discovery & Development 2001. vol. 4, No. 4, pp. 417-427 @ PharmaPress Ltd ISN 1387-6733.
Office Action issued on Jan. 20, 2006 in the corresponding application before the European Patent Office (03 718 393.6-2117).
Response thereto submitted on Jul. 28, 2006 in the corresponding application before the European Patent Office (03 718 393.6-2117).
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14

Affiliated with

Also associated with

Rating

Thrombin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thrombin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3849783